MedWatch

Analyst ahead of H1 report: Strong momentum looks set to continue for Novo Nordisk

The Danish pharmaceutical firm will likely have advanced its GLP-1 and obesity businesses, says an analyst, who has also spotted the signs of a potential guidance upgrade.

Photo: Novo Nordisk / PR

Novo Nordisk, which will report on its second quarter performance on Thursday, has had a flying start to the year.

In Q1, the Danish pharmaceutical firm’s chief executive, Lars Fruergaard Jørgensen, reported of great demand for GLP-1 drugs, including for the company’s bestseller Ozempic -- demand so high that at times, Novo struggled to meet it.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs